Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Barrier Impact of Winlevi in Sensitive Acne Prone Skin
NCT06415292Phase 4Completed
- Sponsor
- Sun Pharma
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clascoterone in acne vulgaris (2 arms), sponsored by Sun Pharma. Primary endpoint: Change in Corneometry Reading Between the Two Sides of the Face Treated With Winlevi Versus no Treatment at 2 weeks. Started Nov 2023; status: completed.
02
Drugs
clascoterone
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT06415292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06415292.